Contribute Try STAT+ Today

The news read like Heritage Foundation fan fiction. Pfizer, a 171-year-old paragon of American industry, was the first to generate truly promising data on a Covid-19 vaccine. And like a pharmaceutical John Henry — or John Galt — the company did it without accepting a single dollar from the federal government and its Operation Warp Speed.

Major drug makers have spent years arguing that their often controversial pricing practices are the essential tradeoff for occasionally world-changing medicines. And here was Pfizer, using only its ample profits to come through with “likely the most significant medical advance in the last 100 years,” as its CEO put it to CNBC.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You neglected to mention that the Pfizer CEO sold $5.6 million in stock the same day he announced their prelim results. Not a victory for corporate altruism.

Comments are closed.